Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ocular Therapeutix (OCUL) Revenue (2016 - 2026)

Ocular Therapeutix has reported Revenue over the past 13 years, most recently at $10.8 million for Q1 2026.

  • For Q1 2026, Revenue rose 0.81% year-over-year to $10.8 million; the TTM value through Mar 2026 reached $52.0 million, down 12.76%, while the annual FY2025 figure was $52.0 million, 18.47% down from the prior year.
  • Revenue for Q1 2026 was $10.8 million at Ocular Therapeutix, down from $13.2 million in the prior quarter.
  • Over five years, Revenue peaked at $17.1 million in Q4 2024 and troughed at $10.7 million in Q1 2025.
  • A 5-year average of $13.9 million and a median of $14.1 million in 2022 define the central range for Revenue.
  • Biggest five-year swings in Revenue: surged 79.61% in 2022 and later decreased 27.59% in 2025.
  • Year by year, Revenue stood at $14.1 million in 2022, then rose by 5.16% to $14.8 million in 2023, then rose by 15.41% to $17.1 million in 2024, then fell by 22.43% to $13.2 million in 2025, then decreased by 18.6% to $10.8 million in 2026.
  • Business Quant data shows Revenue for OCUL at $10.8 million in Q1 2026, $13.2 million in Q4 2025, and $14.5 million in Q3 2025.